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Absolute bioavailability:23-29%.
Mean peak blood 
concentration: 1–2 h after oral 
administration.
Volume of distribution: 3.3 l/kg.
CsA is widely distributed in the 
tissues due to its lipophilic 
character.
Blood levels of cyclosporine in 
field studies were highly 
variable, even among cats with 
similar clinical response.
M E C H A N I S M  O F  AC T I O N
Main objectives of this work are:
• To understand cyclosporine mechanism of action and
pharmacokinetic parameters.
• To make an updated review of its use on feline dermatological conditions.
• To point out and discuss the main adverse reactions.
• To discuss new directions that research could take in the future.
Cyclosporine (CsA) is a lipophilic drug with powerful immunomodulatory and
immunosuppressive properties that has been recently used in immune-mediated
dermatological problems in cats. The licensed product (ATOPICA® for Cats), a modified
version of cyclosporine, is approved for the treatment of feline allergic dermatitis as
manifested by excoriations (including facial and neck), miliary dermatitis, eosinophilic
plaques and self- induced alopecia. However, given its immunomodulatory activity, there
has been much interest in using it in other immune-mediated and allergic dermatologic
conditions in cats, although controlled clinical trials are very limited.
P H A R M AC O K I N E T I C S
King et al. (2012): randomized, double-blinded
placebo controlled study with n=100 cats.
Mean TLS improved >50% in 70% of cats treated
with 7.0mg/kg; compared with 47% in the
2.5mg/kg group and 23% in the placebo group.
Roberts et al. (2016): randomized, double-blinded
placebo controlled study with n=217 cats.
Mean TLS reduction was 65.1% in the treated
group compared with 9.2% in the placebo group.
Owners considered a success in the clinical
response in 78.6% cases in the CsA group vs
26.2% in the placebo group.
Servei de Dermatologia – Fundació HCV
F E L I N E  AT O P I C  S Y N D RO M E
Servei de Dermatologia – Fundació HCV
Vercelli et al. (2006): study with n=8 cats. 4 cats
went into total remission, remaining cats showed
an improvement of clinical signs (40-70%).
Lommer (2013): randomized, placebo-controlled,
double-blinded clinical study with n=16 cats. 7 of
9 cats receiving CsA demonstrated a >40% of
improvement vs 1 of 7 cats in the placebo group.
C H RO N I C  G I N G I VO S T O M AT I T I S
Albert Lloret – Fundació HCV
CsA given at a dose of 7mg/kg/day seems a
good alternative for those patients with an
incorrect response to doxycycline.
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P L A S M A  C E L L  P O D O D E R M AT I T I S
Guaguère & Prèlaud (2000): study with n=12 cats
with EP, EG, IU. Complete regression was achieved
in cats with EP and EG. Cats with IU only achieved
partial regression.
Vercelli et al. (2004): retrospective study with n=7
cats with EP, IU and EG. After 30 days, all animals
showed improvement. Complete remission was
achieved after 60 days (5 cats) and after 90 days (2
cats).
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E O S I N O P H I L I C  G R A N U L O M A
Servei de Dermatologia – Fundació HCV
Irwin et al. (2012): retrospective study with n=15
cats with PF. All cats treated only with CsA were
weaned off GC and scored a good response. One
cat in the CsA group + one cat in the
CsA+Chlorambucile group achieved remission of
PF.
P E M P H I G U S  F O L I AC E U S
Servei de Dermatologia – Fundació HCV
Olivry et al. (2000): report of the use of CsA to
manage an immune-mediated follicutide.
Fontaine & Heimann (2004): report of the use of
CsA to manage 3 Persian cats with idiopathic facial
dermatitis.
Guagère & Fontaine (2004): report of the use of
CsA to manage urticaria pigmentosa in two cats.
Noli & Toma (2006): report of the use of CsA to
manage one cat with sebaceous adenitis.
O T H E R  U S E S
Servei de Dermatologia – Fundació HCV
S I D E  E F F E C T S
I N T RO D U C T I O N
• CsA is a good option for the treatment of cats with Feline Atopic Syndrome.
• It seems a promising therapy for the treatment of several immune-mediated skin
diseases, however, larger scale, randomized, double blinded and placebo-controlled
studies are required.
• Monitoring of the patient during the treatment with CsA is highly advisable.
• Further research is also required in order to establish adverse effects associated with
a long-term use of CsA.
• Development of other routes of administration could also be a good direction for
future research, in order to make easier the administration to cats.
O B J E C T I V E S
C O N C L U S I O N S
CsA + cyclophilin-1  inhibition of calcineurin  stops the activation of NFAT
• Inhibition of IL-2, a T-cell growth promoter, is CsA’s main mechanism of
immunosuppression.
• In cats, CsA has been documented to suppress the transcription of IL-4, IFN-γ, TNF-α,
GM-CSF and IL-10.
• CsA can also affect other cells, including B lymphocytes, antigen presenting cells,
keratinocytes, basophils, mast cells, eosinophils and endothelial cells.
